Mereo BioPharma Group plc (MREO)
| Market Cap | 98.55M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -22.59M |
| Shares Out | 124.99M |
| EPS (ttm) | -0.39 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 551,341 |
| Open | 0.829 |
| Previous Close | 0.829 |
| Day's Range | 0.758 - 0.855 |
| 52-Week Range | 0.301 - 1.850 |
| Beta | 0.84 |
| Analysts | Buy |
| Price Target | 4.34 (+450.41%) |
| Earnings Date | Mar 30, 2023 |
About MREO
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MA... [Read more]
Analyst Forecast
According to 10 analysts, the average rating for MREO stock is "Buy." The 12-month stock price forecast is $4.34, which is an increase of 450.41% from the latest price.
News
Mereo BioPharma Provides Regulatory Updates on Alvelestat for the Treatment of Alpha-1-Antitrypsin Deficiency-Associated Lung Disease
Clear path forward with proposed single Phase 3 study evaluating alvelestat at the 240 mg dose level versus placebo at 12-18 months for potential full approval in both the U.S. and EU
Mereo BioPharma to Participate in Fireside Chat at the SVB Securities Global Biopharma Conference
LONDON, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today a...
MEREO BIOPHARMA (MREO) Loses 25.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for MEREO BIOPHARMA (MREO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street ana...
Mereo BioPharma Received Notification of Nasdaq Minimum Bid Price Deficiency
LONDON, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today ...
Mereo BioPharma Reaches Cooperation Agreement with Rubric Capital Management
Mereo to Appoint Four New Directors to its Board of Directors
Mereo BioPharma to Host Alvelestat R&D Update Call on October 31, 2022
LONDON, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), (“Mereo” or “the Company”), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today ...
Mereo BioPharma Files Shareholder Circular for Upcoming General Meeting
Reiterates Quality and Composition of Mereo's Significantly Refreshed Board, which has the Right Skills and Experience to Guide Mereo's Strategy and Maximize Shareholder Value
Rubric Capital Management Comments on Mereo BioPharma Updated Operating Plan
NEW YORK--(BUSINESS WIRE)--Rubric Capital Management LP (“Rubric”), an investment advisor whose funds and accounts collectively own approximately 14% of the outstanding equity of Mereo BioPharma Group...
Mereo BioPharma Announces Updated Operating Plan to Maximize Shareholder Value
Targets 40% Reduction in Headcount and Significant Expense Reductions as Company Continues to Guide Lead Programs Through Upcoming Value Creating Milestones
Mereo BioPharma Receives FDA Fast Track Designation for Alvelestat for Treatment of Alpha-1 Antitrypsin Deficiency (AATD)-associated Lung Disease
Designation Validates Alvelestat's Potential to Address a Serious Unmet Need
Mereo BioPharma Confirms Receipt of a Valid Notice Requiring it to Convene a General Meeting of Shareholders
Rubric has Rejected Mereo's Reasonable Settlement Proposal and has Escalated its Costly, Distracting Proxy Campaign to Now Seek Control of Mereo's Board
Rubric Capital Management Increases Slate of Proposed Mereo BioPharma Director Nominees to Five
NEW YORK--(BUSINESS WIRE)--Rubric Capital Management LP (“Rubric”), an investment advisor whose funds and accounts collectively own approximately 14% of the outstanding equity of Mereo BioPharma Group...
Mereo BioPharma Offered to Settle Proxy Contest with Rubric Capital Management by Putting Rubric Principal and Second New Director on the Board
Rubric Summarily Rejected the Proposal and Refused to Provide a Counteroffer
Rubric Capital Management Issues Open Letter to Mereo BioPharma Shareholders
NEW YORK--(BUSINESS WIRE)--Rubric Capital Management LP (“Rubric”), an investment advisor whose funds and accounts collectively own approximately 14% of the outstanding equity of Mereo BioPharma Group...
Mereo BioPharma Reports Clinical Update and Interim Biomarker Analysis Presented at ESMO 2022 from ACTIVATE Phase 1b/2 Open Label Study of Etigilimab (Anti-TIGIT Antibody MPH-313) plus Nivolumab (Anti-PD-1 Antibody) in Solid Tumors
Data support further evaluation of PVR, CD226, and TIGIT as potential biomarkers of enrichment for etigilimab plus anti-PD1 therapy
Mereo BioPharma Sends Letter to Rubric Capital Management
Letter Reiterates Mereo's Updated Strategic Plan to Maximize Value for All Shareholders and Corrects Rubric's Assumptions
Mereo BioPharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
LONDON and MOUNTAIN VIEW, Calif., July 05, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), (“Mereo” or “the Company”), a clinical-stage biopharmaceutical company focused on rare dis...
Mereo BioPharma (MREO) Up as AstraZeneca Reportedly Eyes Buyout
Shares of Mereo BioPharma (MREO) surge after reports suggest that AstraZeneca (AZN) is interested in acquiring it.
Why Mereo BioPharma Shares Are Jumping Today
AstraZeneca plc (NASDAQ: AZN) is rumored to be eyeing take over of Mereo BioPharma Group plc (NASDAQ: MREO), according to a report in The Times. The Times' report says that "Mereo would accept $5, equ...
AstraZeneca weighing bid for Mereo BioPharma: report
AstraZeneca AZN, +0.48% AZN, +0.42% is considering a bid for London-based, U.S.-listed biotech Mereo BioPharma MREO, +16.03% , The Times reported without attribution. AstraZeneca already is a partner ...
Mereo BioPharma Announces the Presentation of Updated Data From a Phase 1b/2 Study of Etigilimab as a Poster at the 2022 American Society of Clinical Oncology Annual Meeting
Phase 1b/2 Study of Etigilimab and Nivolumab in Subjects with Select Locally Advanced or Metastatic Solid Tumors (ACTIVATE)
Mereo BioPharma Shares Jump After Encouraging Alvelestat Data In Lung Disease
Mereo BioPharma Group plc (NASDAQ: MREO) has announced topline efficacy and safety results from ASTRAEUS Phase 2 study of alvelestat (MPH-966) in severe alpha-1 antitrypsin deficiency-(AATD) associate...
Mereo BioPharma to Host Conference Call Highlighting Top-line Clinical Data from “ASTRAEUS” Phase 2 Study of Alvelestat
Call scheduled for Monday, May 9, 2022 at 10:30 a.m. ET Call scheduled for Monday, May 9, 2022 at 10:30 a.m. ET
Mereo BioPharma to Host Conferene Call Highlighting Top-line Clinical Data from “ASTRAEUS” Phase 2 Study of Alvelestat
Call scheduled for Monday, May 9, 2022 at 10:30 a.m. ET Call scheduled for Monday, May 9, 2022 at 10:30 a.m. ET
MEREO BIOPHARMA (MREO) Loses 38.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
MEREO BIOPHARMA (MREO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings est...